NCT03248856

Triamcinolone Levels in Cochlear Perilymph

Name: Clinical Trial NCT03248856
Creator: Christoph Arnoldner
Keywords: Cochlear Hearing Loss, Triamcinolone Acetonide, Phase 1, drug, clinical trial, Austria

Christoph Arnoldner·Phase 1·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cochlear Hearing Loss
Drug/Device/Intervention: Triamcinolone Acetonide
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Christoph Arnoldner
Funder: Medical University of Vienna
Location: Vienna, Austria

Timeline & enrollment

Phase: Phase 1
Start date: Oct 02, 2017
End date: May 31, 2021
Enrollment: 40 participants

Primary outcome

Triamcinolone levels in comparison

Summary

In this study Triamcinolone acetonide will be applied intratympanically before cochlear implant surgery. After round window exposure, a perilymph sample and simultaneously a blood sample will be drawn. Triamcinolone levels will then be analyzed in the samples.

ICD-10 classifications

Other hearing lossOther specified hearing lossOtotoxic hearing lossHearing loss, unspecifiedSudden idiopathic hearing loss

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT03248856
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT03248856 through Pure Global AI's free database. This Phase 1 trial is sponsored by Christoph Arnoldner and is currently Completed. The study focuses on Cochlear Hearing Loss. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.